A double blind, randomized, placebo-controlled, adaptive 14-week Phase IIb trial to evaluate the efficacy and safety of vafidemstat in an adult borderline personality disorder (BPD) population (PORTICO)
Latest Information Update: 13 Oct 2024
At a glance
- Drugs Vafidemstat (Primary)
- Indications Borderline personality disorders
- Focus Therapeutic Use
- Acronyms PORTICO
- Sponsors Oryzon
Most Recent Events
- 13 Oct 2024 According to an Oryzon media release, PORTICO's final results were presented at the ECNP New Medication Symposium
- 01 Oct 2024 According to an Oryzon media release, Oryzon invites investors and the general public to join a conference call and webcast with investment analysts today, October 1st, 2024, at 9:00 am EDT (15:00 pm CET) to discuss the outcome of the End-of-Phase II meeting.
- 01 Oct 2024 According to an Oryzon media release, the company announced the receipt of the official meeting minutes from a recent End-of-Phase II meeting for vafidemstat in Borderline Personality Disorder (BPD) with the US Food and Drug Administration (FDA).